關於「Timi 46」標籤，搜尋引擎有相關的訊息討論：

ATLAS ACS-TIMI 46。

ATLAS ACS-TIMI 46 compared the safety and efficacy of rivaroxaban, an oral direct factor Xa inhibitor, to placebo in patients with acute coronary syndromes.： 。

Rivaroxaban versus placebo in patients with acute ... - PubMed。

2009年7月4日 · ATLAS ACS-TIMI 46 study group: E Braunwald, C M Gibson, E Barnathan, J Li, F Misselwitz, L Oppenheimer, J P Bassand, D Bhatt, C Bode, ...： 。

A Pooled Analysis Study of ATLAS ACS‐TIMI 46 and ... - NCBI - NIH。

2019年2月28日 · This study pools data from ATLAS ACS‐TIMI 46 (acute coronary syndrome‐thrombolysis in myocardial infarction 46) trial and ATLAS ACS 2‐TIMI ...： 。

Rivaroxaban versus placebo in patients with acute ... - Europe PMC。

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. J L Mega.： tw | tw。

Prasugrel versus Clopidogrel in Patients with Acute Coronary ...。

2007年11月15日 · TRITON–TIMI 38 was designed as a collaboration between the TIMI Study ... one primary efficacy end point during a 15-month period was 46.： tw | tw。

圖片全部顯示。

ATLAS ACS-TIMI 46 - American College of Cardiology。

2009年6月23日 · Despite percutaneous coronary intervention (PCI) and dual antiplatelet therapy, death or myocardial infarction (MI) at 1 year remain high in ...： 。

2014 AHA/ACC Guideline for the Management of Patients With Non ...。

2014年9月23日 · Timing of Urgent CABG in Patients With NSTE-ACS in Relation to Use of ... 2005; 46:443–9. ... Volz KA, McGillicuddy DC, Horowitz GL, et al.： tw | tw。

Acute Coronary Care in the Elderly, Part I | Circulation - AHA Journals。

The average age of the TIMI IIIb population was 59 years, and only 3% were ≥75 years of age. The subgroup ≥65 years of age demonstrated a 6.9% absolute and 46 ...： tw | tw。

United States Civil Aircraft Register。

... 16516 710 05 46 2 170 3 2 1 1 ZOPP GL PO BOX 132 2384 16517 710 05 46 2 ... 2 170 26 16 SMITH T W ARCFT INC 4490 COOPER RD BALTIMORE 921 30 16572 710 65 ...